Close Menu

NEW YORK – Skin cancer diagnostics company Castle Biosciences reported after the close of the market on Thursday preliminary performance results for the fourth quarter 2019 that showed a 37 percent year-over-year increase in volume for the company's DecisionDx-Melanoma test.

For the three months ended Dec. 31, 2019, the company delivered 4,480 DecisionDx-Melanoma test reports, compared to 3,270 reports during Q4 2018. Castle also delivered 434 DecisionDx-UM test reports for uveal melanoma in Q4, up 13 percent from 385 reports in Q4 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.